The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer:
1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify?
2. What percentage of patients achieve a clinical response?
Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.

Start Date01 Mar 2025

Sponsor / Collaborator

Montefiore Medical Center

[+1]

NCT06411002

/ RecruitingPhase 2

A Phase 2a Study to Evaluate the Effects of DaxibotulinumtoxinA for Injection on the Treatment of Dynamic Forehead Lines and Glabellar Lines

This is a Phase 2a open-label, single-arm study to evaluate the effects of DaxibotulinumtoxinA-lanm (DAXI) for Injection on the treatment of dynamic forehead lines (FHL) and glabellar lines (GL).
Approximately 40 subjects (18 years of age and above) with moderate to severe GL and FHL (all assessed at maximum contraction) will be screened for eligibility with the goal of enrolling and treating 30 subjects to receive DAXI for injection after providing informed consent.
The primary objective of this study is to determine the efficacy and safety of the combined treatment of two upper facial regions with DAXI for injection.

Start Date08 Apr 2024

Sponsor / Collaborator

Revance Therapeutics, Inc.

NCT06225492

/ CompletedPhase 4IIT

Use of DaxibotulinimtoxinA Injection for Platysma Bands of the Neck

This study seeks to evaluate the effectiveness and duration of action of DaxibotulinumtoxinA for neck rejuvenation through treatment of platysmal bands. This study will consist of one treatment visit with subjects being randomized to receiving 15 or 20 units of DaxibotulinumtoxinA per platysmal band. Subjects will return for 5 follow-up visits at 8, 12, 16, 20, and 24 weeks for evaluation.

Start Date01 Jan 2024

Sponsor / Collaborator

Main Line Center for Laser Surgery

100 Clinical Results associated with Daxibotulinumtoixn A-LANM

100 Translational Medicine associated with Daxibotulinumtoixn A-LANM

100 Patents (Medical) associated with Daxibotulinumtoixn A-LANM

Literatures (Medical) associated with Daxibotulinumtoixn A-LANM

01 Mar 2025·OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY

Successful Treatment of Severe, Poorly Controlled Benign Essential Blepharospasm with DaxibotulinumtoxinA

Article

Author: Kikkawa, Don O. ; Sargsyan, Suzan ; Dib El Jalbout, Nahia ; Korn, Bobby S. ; Liu, Catherine Y. ; Al-Sharif, Eman ; Shoji, Marissa K.

Benign essential blepharospasm is a focal dystonia characterized by involuntary contractions of the orbicularis oculi. Botulinum toxin type A injections are often first-line treatment, but patients may experience refractory symptoms or decreased response over time. DaxibotulinumtoxinA, a novel botulinum toxin type A product, has shown promise in cervical dystonia and facial rhytids but has not been previously reported for benign essential blepharospasm treatment. This case highlights a 57-year-old male with severe, poorly controlled benign essential blepharospasm despite high-dose injections of onabotulinumtoxinA and incobotulinumtoxinA. He subsequently received 100 units of daxibotulinumtoxinA in the same periorbital injection pattern with subjective faster onset, extended duration of effect, and improved symptom management compared to previous treatments. Notably, the patient experienced 50% to 75% efficacy retention at 3 months postinjection, significantly better than his response to other botulinum toxin type A products. This case suggests that daxibotulinumtoxinA may be an effective treatment for benign essential blepharospasm including patients experiencing poor symptom control with other botulinum toxin type A products.

01 Feb 2025·PM&R

A randomized, double‐blind, placebo‐controlled trial of DaxibotulinumtoxinA for Injection for the treatment of upper limb spasticity in adults after stroke or traumatic brain injury

Article

Author: Ayyoub, Ziyad ; Kazerooni, Rashid ; Gross, Todd M. ; Munin, Michael C. ; Francisco, Gerard E. ; Patel, Atul T.

Abstract:

Background:

Intramuscular injection of botulinum toxin type A is a first‐line pharmacotherapy for adults with upper limb spasticity (ULS). However, reemergence of symptoms within 12 weeks of treatment is common and longer‐lasting treatments are needed.

Objective:

To evaluate the efficacy and safety of three doses of DaxibotulinumtoxinA for Injection (DAXI) for treatment of ULS in adults with stroke or traumatic brain injury.

Intervention:

Intramuscular injections of placebo (N = 24), DAXI 250 U (N = 22), DAXI 375 U (N = 19), or DAXI 500 U (N = 18) to the suprahypertonic muscle (SMG) and other muscle groups.

Design:

Randomized, double‐blind, placebo‐controlled study.

Setting:

Twenty‐six study centers across the United States.

Participants:

Eighty‐three adult patients with ULS were randomly assigned to each treatment group and followed for up to 36 weeks.

Outcome Measures:

Co‐primary endpoints were the Modified Ashworth Scale (MAS) score change from baseline in the designated SMG and Physician Global Impression of Change (PGIC) at Week 6.

Results:

The mean changes from baseline in MAS score for the designated SMG for placebo and the DAXI 250 U, 375 U, and 500 U groups were −0.6, −0.9, −0.9, and −1.8, respectively, at Week 4 and −0.8, −0.9, −1.0, and −1.5, respectively, at Week 6. Statistically significant improvement in MAS score compared with placebo was reported only for the 500 U dose (Week 4: p < .001; Week 6: p = .049). Significant improvements in PGIC ratings compared with placebo were reported for DAXI 375 U (p = .015) and DAXI 500 U (p = .009) at Week 4 but not for any DAXI doses at Week 6. All DAXI doses were well tolerated with no trend toward more adverse events with increased dose.

Conclusion:

Results from this Phase 2 study indicate that DAXI 500 U is effective and well tolerated for treatment of adults with ULS.

01 Jan 2025·JOURNAL OF VOICE

DaxibotulinumtoxinA Treatment for Laryngeal Respiratory Dystonia

Article

Author: Rosen, Clark A ; Marshall, Camryn

BACKGROUND:

Laryngeal respiratory dystonia (LRD) is diagnosed based on clinical presentation, patient history, and physical examination. Key indicators include dyspnea, desynchronized breathing patterns, and laryngoscopic findings that reveal vocal fold adduction during inspiration. Treatment for LRD remains controversial and often yields limited effectiveness. While botulinum toxin type A (BtxA) is commonly injected into the thyroarytenoid-lateral cricothyroid (TA-LCA) muscle complex, there are cases where injections into the interarytenoid (IA) muscle have also proven beneficial. DaxibotulinumtoxinA (DAXI) is an emerging therapy that has shown promising effectiveness and safety across various conditions, including cervical dystonia. In this report, we present the first documented use of DAXI specifically for LRD, highlighting the significant benefits experienced by the patient compared to previous treatments with BtxA.

CASE:

A 77-year-old man presented with a 1-year history of significant shortness of breath. Laryngeal endoscopy demonstrated inappropriate adduction of the patient's vocal folds during respiration, suggestive of LRD. The patient received their first Botox (BtxA) injection in May 2018 and has since undergone a total of 40 injections. The patient had a variable response to BtxA injection into his TA-LCA muscle complex, experiencing general improvement in breathing but frequent negative impact on voice and swallowing function. In November of 2021, electromyography-guided BtxA injection into the patient's IA muscle was performed with significant improvement in results. The patient described near-complete resolution of his LRD breathing symptoms with minimal voice changes and a duration of benefit of ~50 days. In November of 2023, DAXI injection into the patient's IA muscle was performed. The patient self-reported a complete resolution of his symptoms for a total duration of benefit of 91 days. Subsequent injections with DAXI in February and May of 2024 had near identical responses.

CONCLUSION:

DAXI appears to provide ~80% better duration than the patient's average BtxA injection and a 57% improvement than his best BtxA injection. DAXI is a safe and realistic alternative to BtxA injection in patients with LRD.

News (Medical) associated with Daxibotulinumtoixn A-LANM

17 Mar 2025

·ir.dermatarx.com

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laboratories) to study DMT410 for the treatment of axillary hyperhidrosis - - Raised $2.55 million in gross proceeds from a private placement financing in January 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and certain members of the Company's board of directors - SAN DIEGO, CA / ACCESS Newswire / March 17, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today highlighted recent corporate progress and reported financial results for the year ended December 31, 2024. "I am very proud of what our team has accomplished this year, and we are excited to unblind the topline data from our XYNGARI™ Phase 3 STAR-1 trial in the coming weeks," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. "Our team worked hard to make sure the STAR-1 trial was fully enrolled on schedule so we could keep our promise of a planned announcement of topline data in the first quarter of 2025. I am happy to announce that we fully expect to deliver on this promise, with topline results expected to be unblinded and announced by the end of this month. We are also excited to have recently signed a collaboration agreement with Revance to progress our topical botulinum toxin program forward with an approved toxin product, DAXXIFY®. We believe that Revance sees the potential of this program and will be a great partner to study DMT410 in multiple indications such as hyperhidrosis, acne, and rosacea," concluded Mr. Proehl. Corporate Highlights Completed enrollment in its XYNGARI™ Phase 3 STAR-1 clinical trial in moderate-to-severe acne. After completing enrollment in November 2024, Dermata completed the last patient's last visit in March 2025 and expects to announce topline results from the STAR-1 study by the end of March 2025. STAR-1 is the first of two Phase 3 clinical trials, including a long-term extension study, which the Company will need to complete prior to filing a new drug application with the U.S. Food and Drug Administration. Signed Clinical Trial Collaboration Agreement with Revance, who recently merged with Crown Laboratories. In January 2025, the Company entered into a Clinical Trial Collaboration Agreement with Revance, where the Company and Revance intend to conduct a Phase 2a trial to evaluate XYNGARI™, the Company's topical Spongilla product candidate, with DAXXIFY®, Revance's botulinum toxin product, for the topical treatment of axillary hyperhidrosis. If successful, the companies may agree to further clinical development. Raised $7.8 million in gross proceeds during 2024. The funds raised during 2024, along with the proceeds from the Company's January 2025 PIPE financing, are expected to fund its operations into the third quarter of 2025. Completed enrollment in its XYNGARI™ Phase 3 STAR-1 clinical trial in moderate-to-severe acne. After completing enrollment in November 2024, Dermata completed the last patient's last visit in March 2025 and expects to announce topline results from the STAR-1 study by the end of March 2025. STAR-1 is the first of two Phase 3 clinical trials, including a long-term extension study, which the Company will need to complete prior to filing a new drug application with the U.S. Food and Drug Administration. Signed Clinical Trial Collaboration Agreement with Revance, who recently merged with Crown Laboratories. In January 2025, the Company entered into a Clinical Trial Collaboration Agreement with Revance, where the Company and Revance intend to conduct a Phase 2a trial to evaluate XYNGARI™, the Company's topical Spongilla product candidate, with DAXXIFY®, Revance's botulinum toxin product, for the topical treatment of axillary hyperhidrosis. If successful, the companies may agree to further clinical development. Raised $7.8 million in gross proceeds during 2024. The funds raised during 2024, along with the proceeds from the Company's January 2025 PIPE financing, are expected to fund its operations into the third quarter of 2025. Anticipated Upcoming Milestones Announce topline results in its XYNGARI™ Phase 3 STAR-1 clinical trial in moderate-to-severe acne. Dermata plans to announce topline results from the XYNGARI™ Phase 3 STAR-1 trial by the end of March 2025. Initiate the second XYNGARI™ Phase 3 STAR-2 clinical trial in moderate-to-severe acne. Assuming positive results from the STAR-1 trial, the Company plans to quickly move to initiate the second of two Phase 3 trials of XYNGARI™ for the treatment of moderate-to-severe acne, which will be followed by an extension study. Continue preparation of DMT410 Phase 2a clinical study with Revance. The Company and Revance continue to collaborate on the final study design and start-up procedures to prepare for the Phase 2a clinical study of XYNGARI™ with DAXXIFY® for the topical treatment of axillary hyperhidrosis. Announce topline results in its XYNGARI™ Phase 3 STAR-1 clinical trial in moderate-to-severe acne. Dermata plans to announce topline results from the XYNGARI™ Phase 3 STAR-1 trial by the end of March 2025. Initiate the second XYNGARI™ Phase 3 STAR-2 clinical trial in moderate-to-severe acne. Assuming positive results from the STAR-1 trial, the Company plans to quickly move to initiate the second of two Phase 3 trials of XYNGARI™ for the treatment of moderate-to-severe acne, which will be followed by an extension study. Continue preparation of DMT410 Phase 2a clinical study with Revance. The Company and Revance continue to collaborate on the final study design and start-up procedures to prepare for the Phase 2a clinical study of XYNGARI™ with DAXXIFY® for the topical treatment of axillary hyperhidrosis. Full Year 2024 Financial Results As of December 31, 2024, the Company had $3.2 million in cash and cash equivalents, compared to $7.4 million as of December 31, 2023. The $4.2 million decrease in cash and cash equivalents for the year ended December 31, 2024, resulted from approximately $11.1 million of cash used in operations offset by approximately $6.9 million in net financing proceeds. Including the $2.55 million in gross proceeds from the January 2025 PIPE financing, the Company expects its current cash resources to be sufficient to fund operations into the third quarter of 2025. Research and development expenses were $8.2 million for the year ended December 31, 2024, compared to $4.1 million for the year ended December 31, 2023. The $4.1 million increase in research and development expense for the year ended December 31, 2024, was the result of $4.9 million of increased clinical trial expenses related to running the XYNGARI™ Phase 3 STAR-1 clinical trial, offset by approximately $0.2 million in decreased non-clinical expenses and approximately $0.6 million in decreased chemistry, manufacturing, and controls, or CMC, expenses. General and administrative expenses were $4.3 million for the year ended December 31, 2024, compared to $4.0 million for the year ended December 31, 2023. The increase in general and administrative expenses was primarily attributable to $0.3 million in increased audit related fees as a result of changing auditors in late 2023. About Dermata Therapeutics Dermata Therapeutics is a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications. The Company's lead product candidate, XYNGARI™, is the first product candidate being developed from its Spongilla technology platform. XYNGARI™ is a once-weekly, topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. In addition to acne, XYNGARI™ has been studied for the treatment of psoriasis and rosacea. The Company's second product candidate, DMT410, uses its XYNGARI™ product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple medical skin diseases and applications. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/. Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: expectations with regard to the timing of meetings and/or responses from submissions with regulatory bodies; expectations with regard to the timing of submission of an NDA; the uncertainties inherent in clinical trials including enrolling an adequate number of patients on time or to be completed on schedule, if at all; timing and ability to generate clinical data; expectations with regard to the nature of any clinical data; expectations with regard to any potential partnership opportunities for any of the Company's product candidates; the Company's expectations with regard to current cash and cash equivalents and the amount of time it will fund operations; the success, cost, and timing of its product candidates XYNGARI™ and DMT410 development activities and ongoing and planned clinical trials; and whether the results of any ongoing or planned clinical trials of XYNGARI™ or DMT410 will lead to future product development. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval, and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law. DERMATA THERAPEUTICS, INC. Balance Sheets December 31, 2024 December 31, 2023 $ 3,162 $ 7,438 372 541 3,534 7,979 808 866 1,165 757 1,973 1,623 1,561 6,356 $ 3,534 $ 7,979 DERMATA THERAPEUTICS, INC. Statements of Operations Year Ended December 31, 2024 2023 $ 8,204 $ 4,070 4,309 3,972 12,513 8,042 (12,513 ) (8,042 ) 226 247 $ (12,287 ) $ (7,795 ) $ (8.03 ) $ (39.99 ) 1,529,772 194,928 $ 251 $ 194 $ 406 $ 328 Investors: Cliff Mastricola Investor Relations cmastricola@dermatarx.com SOURCE: Dermata Therapeutics Released March 17, 2025

Phase 3Financial StatementPhase 2

25 Feb 2025

·ir.dermatarx.com

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis - - The Company also has an issued patent in Japan covering their DMT410 program for the treatment of hyperhidrosis - SAN DIEGO, CA / ACCESS Newswire / February 25, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced the Australian Patent Office has accepted its patent application for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled "Compositions for the treatment of skin conditions," (Australian Patent Application No. 2109284621) continues to strengthen Dermata's global intellectual property portfolio for DMT410 for the treatment of hyperhidrosis. The patent will be automatically issued three months after acceptance unless a third party files an opposition. "We are thrilled to receive this acceptance as we believe it further validates DMT410's innovative approach to delivering botulinum toxin topically for the treatment of hyperhidrosis," said Gerry Proehl, Dermata's Chairman, President, and CEO. "We see significant opportunities for our DMT410 program, and we are eager to move forward with our planned Phase 2a study in collaboration with Revance Therapeutics, who also has DAXXIFY® approved in Australia. This Phase 2a study will explore DMT410, which combines a single application of XYNGARI™ followed by a topical application of DAXXIFY® for the treatment of axillary hyperhidrosis. Beyond hyperhidrosis, we believe DMT410 holds promise as a versatile treatment for a range of skin conditions, including acne, rosacea, melasma, acne scars, and other aesthetic concerns that are in need of more effective solutions," Mr. Proehl added. About DMT410 DMT410 is the Company's combination treatment regimen that uses the unique mechanical features of the Company's XYNGARI™ product candidate to facilitate the intradermal delivery of botulinum toxin by topical application rather than through multiple injections with a needle. The treatment consists of an initial topical application of XYNGARI™ to the treatment area where the microscopic spicules penetrate the stratum corneum to create microchannels into the dermis allowing for the topical application and penetration of botulinum toxin. The Company has successfully completed proof-of-concept Phase 1 clinical trials using DMT410 in combination with BOTOX® for the treatment of primary axillary hyperhidrosis and for the treatment of multiple aesthetic skin conditions. Both studies showed promising efficacy results and appeared to be safe and well tolerated by patients. The Company is also planning to initiate a Phase 2a study of DMT410 (XYNGARI™ with DAXXIFY®) for the treatment of axillary hyperhidrosis. About Dermata Therapeutics Dermata Therapeutics is a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions. Dermata's lead product candidate, XYNGARI™ (formerly DMT310), is its first product candidate being developed from its Spongilla technology platform. XYNGARI™ is a once-weekly, topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. In addition to acne, XYNGARI™ has been studied for the treatment of psoriasis and rosacea. Dermata's second program, uses XYNGARI™ as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin diseases and conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/. Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: expectations with regard to the timing of meetings and/or responses from submissions with regulatory bodies, including the FDA; the uncertainties inherent in clinical trials; expectations with regard to any potential partnership opportunities for any of the Company's product candidates; the Company's expectations with regard to current cash and cash equivalents and the amount of time it will fund operations; the success, cost, and timing of its product candidate DMT410 development activities and ongoing and planned clinical trials; whether the results of any planned clinical trials of DMT410 will lead to future product development; whether pending patent applications will proceed to allowance without interruption, if at all; and whether pending, accepted, or issued patents will provide adequate protection for the Company's product candidates, if approved. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval, and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law. Investors: Cliff Mastricola Investor Relations cmastricola@dermatarx.com SOURCE: Dermata Therapeutics Released February 25, 2025

Phase 1Phase 2

05 Feb 2025

·endpts.com

Revance and Crown are almost ready to close their deal after earlier bidding war

The fight over who gets control of Revance Therapeutics and its Botox competitor, Daxxify, is coming to a close. On Wednesday, Revance said it’s moving forward with its sale to Crown Laboratories. The two companies had been in talks for months when, in January, Revance’s commercial partner Teoxane submitted a competing bid . Crown had initially offered $6.66 per share in August to acquire Revance. Shortly after, Teoxane initiated a contract dispute with Revance that delayed the deal and was a factor in Crown’s decision to slash its offer to $3.10 a share. Teoxane, which develops dermal fillers, then proposed to buy Revance for $3.60 per share. Teoxane argued that its offer was a “superior, attractive and actionable alternative” to Crown’s deal. But Crown CEO Jeff Bedard said in a letter to Revance’s board of directors that Teoxane’s actions “have been clearly designed to disrupt a transaction involving Revance and Crown, to the significant detriment of Revance and its stockholders.” Revance said it would talk to Teoxane about its offer. But when Crown raised its bid to $3.65 per share late last month, Revance said the Crown proposal was “the only fully financed offer currently available.” The companies expect to close the deal on Thursday, they announced in a joint press release. Daxxify has been approved since 2022 as a treatment for moderate-to-severe glabellar lines, otherwise known as frown lines. It’s also approved to treat cervical dystonia, a condition in which the neck muscles contract uncontrollably. However, Crown has expressed a particular interest in the aesthetics side of Revance’s business.

Drug ApprovalAcquisition

100 Deals associated with Daxibotulinumtoixn A-LANM

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dystonic Disorders	China	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	22 Nov 2024
cervical dystonia	United States	Revance Therapeutics, Inc.	11 Aug 2023
Glabellar frown lines	United States	Revance Therapeutics, Inc.	07 Sep 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Torticollis	NDA/BLA	United States	Revance Therapeutics, Inc.	20 Oct 2022
Isolated cervical dystonia	Phase 3	United States	Revance Therapeutics, Inc.	05 Sep 2018
Isolated cervical dystonia	Phase 3	Austria	Revance Therapeutics, Inc.	05 Sep 2018
Isolated cervical dystonia	Phase 3	Canada	Revance Therapeutics, Inc.	05 Sep 2018
Isolated cervical dystonia	Phase 3	Czechia	Revance Therapeutics, Inc.	05 Sep 2018
Isolated cervical dystonia	Phase 3	France	Revance Therapeutics, Inc.	05 Sep 2018
Isolated cervical dystonia	Phase 3	Germany	Revance Therapeutics, Inc.	05 Sep 2018
Isolated cervical dystonia	Phase 3	Poland	Revance Therapeutics, Inc.	05 Sep 2018
Isolated cervical dystonia	Phase 3	Spain	Revance Therapeutics, Inc.	05 Sep 2018
Isolated cervical dystonia	Phase 3	United Kingdom	Revance Therapeutics, Inc.	05 Sep 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAN2024	Not Applicable	cervical dystonia	-	DaxibotulinumtoxinA	xmmifqmebo(sigfkcdrpq) = xwqkllcrns fazqbomhvq (pfssklcvtt ) View more	-	09 Apr 2024
AAN2024	Not Applicable	cervical dystonia	-	DaxibotulinumtoxinA for injection (DAXI) 250U	jbjmywqkbd(auitbrwisq) = jssgrzukgb nryztrysjs (xetxdyucwe )	-	09 Apr 2024
NCT02973269 (CTgov)	Phase 2	Fasciitis, Plantar	7	daxibotulinumtoxin type A (DAXI 240 U)	rqpzlqwaka(fviooreank) = ixaqxktihp ynqmklxafj (huphcmgnfu, 11.0) View more	-	03 Apr 2024
				Placebo (Placebo)	rqpzlqwaka(fviooreank) = yewvrgiqla ynqmklxafj (huphcmgnfu, 12.1) View more
NCT03608397 \| EUCTR2018-000446-19-AT (ASPEN-1, Pubmed \| Neurology) Manual	Phase 3	cervical dystonia	301	DAXI125U	cphigolihu(gdtjmutrcr) = erhulgtzqw klcwxdhant (umzlbjwexi, 1.30) View more	Positive	31 Jan 2024
				DAXI250U	cphigolihu(gdtjmutrcr) = sebpdwyqsx klcwxdhant (umzlbjwexi, 1.25) View more
NCT03825315 (CTgov)	Phase 2	Fasciitis, Plantar	155	DAXI 80 U (DAXI 80 U)	ijaauzebjy(gyxoxkycbh) = ldzzbjnolg numfkfqapk (xrswgmnulm, 0.329) View more	-	21 Sep 2023
				DAXI 120 U (DAXI 120 U)	ijaauzebjy(gyxoxkycbh) = essobmevxw numfkfqapk (xrswgmnulm, 0.298) View more
GL-2 (FDA) Manual	Not Applicable	Glabellar frown lines	609	DAXXIFY (STUDY GL-1)	qkeeuwpanz(lhmhvyuwwl) = andfplrhrg qxdtnamaou (fxoobynmxb ) View more	Positive	11 Aug 2023
				Placebo (STUDY GL-1)	qkeeuwpanz(lhmhvyuwwl) = cjdtfkdbel qxdtnamaou (fxoobynmxb ) View more
NCT03608397 (FDA) Manual	Phase 3	cervical dystonia	301	Placebo	ieccnyayye(cnwceymxsm) = ghmuzmwvsi iiksswucpu (oqpptjndyu )	Positive	11 Aug 2023
				DAXI 125 U	ieccnyayye(cnwceymxsm) = eqakrnuxcs iiksswucpu (oqpptjndyu )
NCT04259086 (CTgov)	Phase 2	Glabellar frown lines	48	DaxibotulinumtoxinA for injection	kwmmpovkxk = hutreozouc vufcgpmqcg (eabljsbsmu, xtmeylpdao - kdnwemvdfb) View more	-	27 Jun 2023
NCT03911102 (CTgov)	Phase 2	Lateral Canthal Lines	63	DaxibotulinumtoxinA for injection (Cohort 1: DAXI 12 U)	uzuowxzjcd = qxhnqqkzda oxanidaajd (mdirdzqayo, xozeffvguc - fsunnlmkmj) View more	-	27 Jun 2023
				DaxibotulinumtoxinA for injection (Cohort 2: DAXI 24 U)	uzuowxzjcd = exjpfdaulg oxanidaajd (mdirdzqayo, hlwpavvtmv - vocpqtyppe) View more
ASPEN-1 and ASPEN-OLS (AAN2023)	Phase 3	cervical dystonia	-	Placebo	blroamxkdc(mglzcxdpca) = tqnrtrmcya xerpzvvzaw (znffhzrqkz )	Positive	25 Apr 2023
				DAXI 125U	blroamxkdc(mglzcxdpca) = evbngjkxor xerpzvvzaw (znffhzrqkz )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis